ZHENG R S , ZHANG S W , ZENG H M , et al . Cancer incidence and mortality in China, 2016 [J ] . J Natl Cancer Cent , 2022 , 2 ( 1 ): 1 - 9 .

MOLINA J R , YANG P , CASSIVI S D , et al . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship [J ] . Mayo Clin Proc , 2008 , 83 ( 5 ): 584 - 594 . DOI: 10.1016/S0025-6196(11)60735-0 http://doi.org/10.1016/S0025-6196(11)60735-0 https://linkinghub.elsevier.com/retrieve/pii/S0025619611607350 https://linkinghub.elsevier.com/retrieve/pii/S0025619611607350

YANG C Y , YANG J C H , YANG P C . Precision management of advanced non-small cell lung cancer [J ] . Annu Rev Med , 2020 , 71 : 117 - 136 . DOI: 10.1146/annurev-med-051718-013524 http://doi.org/10.1146/annurev-med-051718-013524 https://www.annualreviews.org/doi/10.1146/annurev-med-051718-013524 https://www.annualreviews.org/doi/10.1146/annurev-med-051718-013524

RECK M , RODRÍGUEZ-ABREU D , ROBINSON A G , et al . Pembrolizumab versus chemotherapy for PD-L1-positive non-small cell lung cancer [J ] . N Engl J Med , 2016 , 375 ( 19 ): 1823 - 1833 . DOI: 10.1056/NEJMoa1606774 http://doi.org/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774 http://www.nejm.org/doi/10.1056/NEJMoa1606774

BRAHMER J R , RODRIGUEZ-ABREU D , ROBINSON A G , et al. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) & #x02265;50% [J ] . Ann Oncol , 2020 , 31 : S1181-S1182.

HERBST R S , GIACCONE G , DE MARINIS F , et al . Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC [J ] . N Engl J Med , 2020 , 383 ( 14 ): 1328 - 1339 . DOI: 10.1056/NEJMoa1917346 http://doi.org/10.1056/NEJMoa1917346 http://www.nejm.org/doi/10.1056/NEJMoa1917346 http://www.nejm.org/doi/10.1056/NEJMoa1917346

JASSEM J , DE MARINIS F , GIACCONE G , et al . Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 11 ): 1872 - 1882 . DOI: 10.1016/j.jtho.2021.06.019 http://doi.org/10.1016/j.jtho.2021.06.019 https://linkinghub.elsevier.com/retrieve/pii/S1556086421022863 https://linkinghub.elsevier.com/retrieve/pii/S1556086421022863

SEZER A , KILICKAP S , GÜMÜŞ M , et al . Cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial [J ] . Lancet , 2021 , 397 ( 10274 ): 592 - 604 . DOI: 10.1016/S0140-6736(21)00228-2 http://doi.org/10.1016/S0140-6736(21)00228-2 https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282 https://linkinghub.elsevier.com/retrieve/pii/S0140673621002282

RECK M , RODRÍGUEZ-ABREU D , ROBINSON A G , et al . Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50 [J ] . J Clin Oncol , 2021 , 39 ( 21 ): 2339 - 2349 . DOI: 10.1200/JCO.21.00174 http://doi.org/10.1200/JCO.21.00174 https://ascopubs.org/doi/10.1200/JCO.21.00174 https://ascopubs.org/doi/10.1200/JCO.21.00174

HWANG D M , ALBAQER T , SANTIAGO R C , et al . Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1490 - 1500 . DOI: 10.1016/j.jtho.2021.03.028 http://doi.org/10.1016/j.jtho.2021.03.028 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021080 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021080

GANDHI L , RODRÍGUEZ-ABREU D , GADGEEL S , et al . Pembrolizumab plus chemotherapy in metastatic non-small cell lung cancer [J ] . N Engl J Med , 2018 , 378 ( 22 ): 2078 - 2092 . DOI: 10.1056/NEJMoa1801005 http://doi.org/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005 http://www.nejm.org/doi/10.1056/NEJMoa1801005

GADGEEL S , GARASSINO M C , ESTEBAN E , et al . KEYNOTE-189: OS update and progression after the next line of therapy (PFS2) with pembrolizumab + chemotherapy for metastatic nonsquamous NSCLC [J ] . J Thorac Oncol , 2019 , 14 ( 11 ): S1153 .

PAZ-ARES L , LUFT A , VICENTE D , et al . Pembrolizumab plus chemotherapy for squamous non-small cell lung cancer [J ] . N Engl J Med , 2018 , 379 ( 21 ): 2040 - 2051 . DOI: 10.1056/NEJMoa1810865 http://doi.org/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865 http://www.nejm.org/doi/10.1056/NEJMoa1810865

PAZ-ARES L , VICENTE D , TAFRESHI A , et al . A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407 [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1657 - 1669 . DOI: 10.1016/j.jtho.2020.06.015 http://doi.org/10.1016/j.jtho.2020.06.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305001 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305001

ZHOU C C , CHEN G Y , HUANG Y C , et al . Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial [J ] . Lancet Respir Med , 2021 , 9 ( 3 ): 305 - 314 . DOI: 10.1016/S2213-2600(20)30365-9 http://doi.org/10.1016/S2213-2600(20)30365-9 https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659 https://linkinghub.elsevier.com/retrieve/pii/S2213260020303659

YANG Y P , WANG Z H , FANG J , et al . Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (oncology program by innovent anti-PD-1-11) [J ] . J Thorac Oncol , 2020 , 15 ( 10 ): 1636 - 1646 . DOI: 10.1016/j.jtho.2020.07.014 http://doi.org/10.1016/j.jtho.2020.07.014 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305955 https://linkinghub.elsevier.com/retrieve/pii/S1556086420305955

YANG Y P , SUN J Y , WANG Z H , et al . Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study [J ] . J Thorac Oncol , 2021 , 16 ( 12 ): 2109 - 2120 . DOI: 10.1016/j.jtho.2021.07.015 http://doi.org/10.1016/j.jtho.2021.07.015 https://linkinghub.elsevier.com/retrieve/pii/S1556086421023303 https://linkinghub.elsevier.com/retrieve/pii/S1556086421023303

LU S , WANG J , YU Y , et al . Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC (RATIONALE 304): a randomized phase 3 trial [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1512 - 1522 . DOI: 10.1016/j.jtho.2021.05.005 http://doi.org/10.1016/j.jtho.2021.05.005 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021766 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021766

ZHOU C , REN S , CHEN J , et al . Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): a randomized, double-blind, multicenter, phase Ⅲ trial [J ] . J Thorac Oncol , 2021 , 16 ( 4 ): S748.

WANG J , LU S , HU C , et al . Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC) [J ] . Ann Oncol , 2020 , 31 : S817.

ZHOU C C , WU L , FAN Y , et al . Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase 3 trial (ORIENT-12) [J ] . J Thorac Oncol , 2021 , 16 ( 9 ): 1501 - 1511 . DOI: 10.1016/j.jtho.2021.04.011 http://doi.org/10.1016/j.jtho.2021.04.011 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021286 https://linkinghub.elsevier.com/retrieve/pii/S1556086421021286

ZHOU C C , WANG Z P , SUN Y P , et al . Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial [J ] . Lancet Oncol , 2022 , 23 ( 2 ): 220 - 233 . DOI: 10.1016/S1470-2045(21)00650-1 http://doi.org/10.1016/S1470-2045(21)00650-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501 https://linkinghub.elsevier.com/retrieve/pii/S1470204521006501

WANG J , WANG Z , WU L , et al . CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): S927-S928 .

RECK M , JOTTE R , CAPPUZZO F , et al . IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) [J ] . Pneumologie , 2020 , 74 : S39-S39

YANG J C H , LUFT A , DE LA MORA JIMÉNEZ E , et al . Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): a phase Ⅲ, randomized, double-blind study [J ] . Ann Oncol , 2021 , 32 : S1429-S1430.

NISHIO M , PELED N , ZER A , et al . Phase Ⅲ LEAP-006 safety Run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC [J ] . Ann Oncol , 2020 , 31 : S848-S849.

REN S X , HE J X , FANG Y , et al . Camrelizumab plus apatinib in treatment-naive patients with advanced nonsquamous NSCLC: a multicenter, open-label, single-arm, phase 2 trial [J ] . JTO Clin Res Rep , 2022 , 3 ( 5 ): 100312 .

HAN B H , CHEN J , XIE Q , et al . A multicenter, randomized, phase 3 trial of penpulimab in combination with anlotinib or chemotherapy as first-line treatment in advanced NSCLC [J ] . J Thorac Oncol Off Publ Int Assoc Study Lung Cancer , 2021 , 16 ( 3 ): S650.

CHU T Q , ZHONG R B , ZHONG H , et al . Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC [J ] . J Thorac Oncol , 2021 , 16 ( 4 ): 643 - 652 . DOI: 10.1016/j.jtho.2020.11.026 http://doi.org/10.1016/j.jtho.2020.11.026 https://linkinghub.elsevier.com/retrieve/pii/S1556086420311011 https://linkinghub.elsevier.com/retrieve/pii/S1556086420311011

ZHAO S , REN S X , JIANG T , et al . Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer [J ] . Cancer Immunol Res , 2019 , 7 ( 4 ): 630 - 643 . DOI: 10.1158/2326-6066.CIR-17-0640 http://doi.org/10.1158/2326-6066.CIR-17-0640 https://aacrjournals.org/cancerimmunolres/article/7/4/630/469459/Low-Dose-Apatinib-Optimizes-Tumor-Microenvironment https://aacrjournals.org/cancerimmunolres/article/7/4/630/469459/Low-Dose-Apatinib-Optimizes-Tumor-Microenvironment

HELLMANN M D , PAZ-ARES L , BERNABE CARO R , et al . Nivolumab plus ipilimumab in advanced non-small cell lung cancer [J ] . N Engl J Med , 2019 , 381 ( 21 ): 2020 - 2031 . DOI: 10.1056/NEJMoa1910231 http://doi.org/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231 http://www.nejm.org/doi/10.1056/NEJMoa1910231

PAZ-ARES L G , RAMALINGAM S S , CIULEANU T E , et al . First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial [J ] . J Thorac Oncol , 2022 , 17 ( 2 ): 289 - 308 . DOI: 10.1016/j.jtho.2021.09.010 http://doi.org/10.1016/j.jtho.2021.09.010 https://linkinghub.elsevier.com/retrieve/pii/S155608642103207X https://linkinghub.elsevier.com/retrieve/pii/S155608642103207X

PAZ-ARES L , CIULEANU T E , COBO M , et al . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 2 ): 198 - 211 . DOI: 10.1016/S1470-2045(20)30641-0 http://doi.org/10.1016/S1470-2045(20)30641-0 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410 https://linkinghub.elsevier.com/retrieve/pii/S1470204520306410

JOHN T , SAKAI H , IKEDA S , et al. First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA [J ] . Ann Oncol , 2020 , 31 : S847-S848.

JOHNSON M , CHO B C , LUFT A , et al . Durvalumab ± tremelimumab + chemotherapy as first-line treatment for mNSCLC: results from the phase 3 POSEIDON study [J ] . J Thorac Oncol , 2021 , 16 ( 10 ): S844.

ABREU D R , RECK M , ŞENDUR N , et al . Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up [J ] . Ann Oncol , 2022 , 33 : S30-S31.

MARUHASHI T , SUGIURA D , OKAZAKI I M , et al . LAG-3: from molecular functions to clinical applications [J ] . J Immunother Cancer , 2020 , 8 ( 2 ): e001014.

HODI F S , TAWBI H A , LIPSON E J , et al . Relatlimab (RELA) + nivolumab (NIVO) vs NIVO in previously untreated metastatic or unresectable melanoma: additional efficacy in RELATIV ITY-047 [J ] . Ann Oncol , 2021 , 32 : S867-S868.

MORGENSZTERN D , CHAUDHRY A , IANNOTTI N , et al . RELATIVITY-104: First-line relatlimab (RELA) + nivolumab (NIVO) with chemotherapy vs NIVO with chemotherapy in stage & #x02163; or recurrent non-small cell lung cancer (NSCLC): a phase & #x02161;, randomized, double-blind study [J ] . Ann Oncol , 2021 , 32 : S1030.

CHAUVIN J M , ZAROUR H M . TIGIT in cancer immunotherapy [J ] . J Immunother Cancer , 2020 , 8 ( 2 ): e000957.

CHO B C , ABREU D R , HUSSEIN M , et al . Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study [J ] . Lancet Oncol , 2022 , 23 ( 6 ): 781 - 792 . DOI: 10.1016/S1470-2045(22)00226-1 http://doi.org/10.1016/S1470-2045(22)00226-1 https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261 https://linkinghub.elsevier.com/retrieve/pii/S1470204522002261

MARIN-ACEVEDO J A , KIMBROUGH E O , LOU Y Y . Next generation of immune checkpoint inhibitors and beyond [J ] . J Hematol Oncol , 2021 , 14 ( 1 ): 45 . DOI: 10.1186/s13045-021-01056-8 http://doi.org/10.1186/s13045-021-01056-8 https://doi.org/10.1186/s13045-021-01056-8 https://doi.org/10.1186/s13045-021-01056-8

PAZ-ARES L , KIM T M , VICENTE D , et al . Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial [J ] . J Thorac Oncol , 2020 , 15 ( 7 ): 1210 - 1222 . DOI: 10.1016/j.jtho.2020.03.003 http://doi.org/10.1016/j.jtho.2020.03.003 https://linkinghub.elsevier.com/retrieve/pii/S1556086420301957 https://linkinghub.elsevier.com/retrieve/pii/S1556086420301957

WU L , CHEN B , YAO W , et al . A phase Ⅰb/Ⅱ trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC [J ] . Ann Oncol , 2021 , 32 : S1006.

HONG M H , CLUBB J D , CHEN Y Y . Engineering CAR-T cells for next-generation cancer therapy [J ] . Cancer Cell , 2020 , 38 ( 4 ): 473 - 488 . DOI: 10.1016/j.ccell.2020.07.005 http://doi.org/10.1016/j.ccell.2020.07.005 https://linkinghub.elsevier.com/retrieve/pii/S1535610820303664 https://linkinghub.elsevier.com/retrieve/pii/S1535610820303664

QU J J , MEI Q H , CHEN L J , et al . Chimeric antigen receptor (CAR)-T-cell therapy in non-small cell lung cancer (NSCLC): current status and future perspectives [J ] . Cancer Immunol Immunother , 2021 , 70 ( 3 ): 619 - 631 . DOI: 10.1007/s00262-020-02735-0 http://doi.org/10.1007/s00262-020-02735-0 https://doi.org/10.1007/s00262-020-02735-0 https://doi.org/10.1007/s00262-020-02735-0

YILMAZ A , CUI H W , CALIGIURI M A , et al . Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 168 . DOI: 10.1186/s13045-020-00998-9 http://doi.org/10.1186/s13045-020-00998-9 https://doi.org/10.1186/s13045-020-00998-9 https://doi.org/10.1186/s13045-020-00998-9

GOULDING J , BLUM R , HANCOCK B , et al . Abstract 1591: FT536: preclinical development of a novel off-the-shelf CAR-MICA/B NK cell immunotherapy combined with radiation and antibody treatments as a first-of-kind pan-cancer targeting strategy [J ] . Cancer Res , 2021 , 81 ( 13_Supplement ): 1591 . DOI: 10.1158/1538-7445.AM2021-1591 http://doi.org/10.1158/1538-7445.AM2021-1591 https://aacrjournals.org/cancerres/article/81/13_Supplement/1591/667388/Abstract-1591-FT536-Preclinical-development-of-a https://aacrjournals.org/cancerres/article/81/13_Supplement/1591/667388/Abstract-1591-FT536-Preclinical-development-of-a

HEMMINKI O , DOS SANTOS J M , HEMMINKI A . Oncolytic viruses for cancer immunotherapy [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 84 . DOI: 10.1186/s13045-020-00922-1 http://doi.org/10.1186/s13045-020-00922-1 https://doi.org/10.1186/s13045-020-00922-1 https://doi.org/10.1186/s13045-020-00922-1

SAXENA M , VAN DER BURG S H , MELIEF C J M , et al . Therapeutic cancer vaccines [J ] . Nat Rev Cancer , 2021 , 21 ( 6 ): 360 - 378 . DOI: 10.1038/s41568-021-00346-0 http://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0